Orchid Pharma Ltd
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]
- Market Cap ₹ 3,707 Cr.
- Current Price ₹ 731
- High / Low ₹ 1,998 / 604
- Stock P/E 37.2
- Book Value ₹ 250
- Dividend Yield 0.00 %
- ROCE 8.02 %
- ROE 8.18 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 22.5% CAGR over last 5 years
Cons
- Stock is trading at 2.93 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has a low return on equity of 7.04% over last 3 years.
- Promoter holding has decreased over last 3 years: -20.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Sep 2013 18m | Mar 2015 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,948 | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 922 | |
1,837 | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 805 | |
Operating Profit | 110 | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 117 |
OPM % | 6% | 18% | 20% | 0% | 4% | -2% | -6% | 7% | 10% | 13% | 14% | 13% |
92 | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 27 | |
Interest | 523 | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 15 |
Depreciation | 252 | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 35 |
Profit before tax | -573 | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 96 |
Tax % | -2% | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | -0% |
-560 | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 100 | |
EPS in Rs | -79.21 | -23.06 | -31.37 | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 19.65 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -6% |
5 Years: | 14% |
3 Years: | 18% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 23% |
3 Years: | 249% |
TTM: | 8% |
Stock Price CAGR | |
---|---|
10 Years: | 29% |
5 Years: | % |
3 Years: | 38% |
1 Year: | -35% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | 7% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 70 | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 |
Reserves | 310 | 244 | -40 | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,217 |
3,204 | 3,211 | 3,215 | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 175 | |
1,067 | 521 | 598 | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 246 | |
Total Liabilities | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
2,584 | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 649 | |
CWIP | 360 | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 64 |
Investments | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 50 |
1,706 | 1,984 | 1,944 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 925 | |
Total Assets | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
168 | -369 | 212 | 401 | 9 | 12 | 81 | 24 | 92 | 18 | 126 | 19 | |
-986 | 1,334 | -1 | -176 | -28 | 45 | 167 | 67 | 113 | -31 | -312 | -27 | |
664 | -597 | -286 | -465 | 33 | -0 | -250 | -165 | -217 | 31 | 167 | 25 | |
Net Cash Flow | -153 | 367 | -76 | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 18 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 34 | 54 | 130 | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 | 96 |
Inventory Days | 187 | 118 | 220 | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 | 219 |
Days Payable | 220 | 146 | 341 | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 | 149 |
Cash Conversion Cycle | -0 | 26 | 9 | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 | 166 |
Working Capital Days | -113 | 86 | 97 | -226 | -505 | -735 | 166 | 305 | 136 | 154 | 124 | 152 |
ROCE % | -3% | 1% | 1% | -4% | -4% | -5% | -6% | -5% | -2% | 5% | 9% | 8% |
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
1d - Orchid Pharma shareholders approve amalgamation scheme with Dhanuka Laboratories, over 97% votes in favor.
-
Announcement under Regulation 30 (LODR)-Change in Management
1d - Re-appointment of three independent directors for five years from June 29, 2025.
- Closure of Trading Window 26 Jun
- Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting 26 Jun
- Intimation Of Record Date For Voting Rights Of Shareholders W.R.T. The Meeting Of Equity Shareholders Of Orchid Pharma Limited ("Company"/ "Amalgamated Company") Convened Pursuant To The Order Passed By Hon''ble National Company Law Tribunal, For Considering And Approving The Scheme Of Amalgamation Of The Dhanuka Laboratories Limited ("Amalgamating Company") With The Company And Their Respective Shareholders And Creditors ("The Scheme") 9 Jun
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Nov 2023TranscriptNotesPPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jun 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Dec 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
Product Segments FY24
The company operates mainly in the Cephalosporins-based active pharmaceutical ingredients (API) business. These APIs are primarily used in anti-bacterial, anti-biotic, and anti-inflammatory formulations. [1][2]